^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    GPRC5D inhibitor

    Related drugs:
    7d
    Talisman: A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events (clinicaltrials.gov)
    P2, N=210, Recruiting, Janssen Research & Development, LLC | N=130 --> 210
    Enrollment change
    |
    Talvey (talquetamab-tgvs)
    9d
    Talquetamab in Patients With Refractory Generalized Myasthenia Gravis (clinicaltrials.gov)
    P=N/A, N=2, Not yet recruiting, First Affiliated Hospital of Chongqing Medical University
    New trial
    |
    Talvey (talquetamab-tgvs)
    14d
    A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma (clinicaltrials.gov)
    P1, N=87, Recruiting, Sanofi | Trial completion date: May 2029 --> May 2031 | Trial primary completion date: Nov 2028 --> May 2031
    Trial completion date • Trial primary completion date • First-in-human
    1m
    A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=150, Not yet recruiting, Regeneron Pharmaceuticals
    New P1/2 trial • First-in-human
    |
    Lynozyfic (linvoseltamab-gcpt)
    1m
    A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy (clinicaltrials.gov)
    P2, N=17, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Oct 2026 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Talvey (talquetamab-tgvs)
    1m
    MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, University of Arkansas | Initiation date: Apr 2026 --> Jul 2026
    Trial initiation date
    |
    clonoSEQ
    |
    lenalidomide • Darzalex (daratumumab) • melphalan • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    1m
    A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=228, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Xpovio (selinexor) • dexamethasone • pomalidomide • QLS32015
    2ms
    EMN37: Study for frail patients with newly diagnosed multiple myeloma treated with Daratumumab in combination with Teclistamab and Talquetamab. (2024-520433-76-00)
    P1/2, N=150, Recruiting, European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale
    New P1/2 trial
    |
    Darzalex (daratumumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    2ms
    A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=157, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    JNJ-5322
    2ms
    Talisman: A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity (clinicaltrials.gov)
    P2, N=130, Recruiting, Janssen Research & Development, LLC | Trial completion date: Oct 2027 --> Apr 2029
    Trial completion date
    |
    Talvey (talquetamab-tgvs)
    2ms
    MonumenTAL-8: A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=11, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Nov 2026 --> Aug 2027
    Trial completion date
    |
    Carvykti (ciltacabtagene autoleucel) • Talvey (talquetamab-tgvs)
    2ms
    MonumenTAL-1: Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=279, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2029 --> Oct 2027
    Trial completion date • First-in-human
    |
    Talvey (talquetamab-tgvs)